This article addresses limited vaccination coverage by providing an overview of the epidemiology of influenza, pertussis, and pneumonia, and the impact these diseases have on work attendance for the worker, the worker's family, and employer profit. Studies focused on the cost of vaccination programs, lost work time, lost employee productivity and acute disease treatment are discussed, as well as strategies for increasing vaccination coverage to reduce overall health care costs for employers. Communicating the benefits of universal vaccination for employees and their families and combating vaccine misinformation among employees are outlined.
References
1.
ApplebyJ. (2009). The costs of pandemic flu. British Journal of Healthcare Management, 15, 215.
2.
BaggettH.DuchinJ.SheltonW.ZerrD.HeathJ.Ortega-SanchezI.TiwariT. (2007). Two nosocomial pertussis outbreaks and their associated costs—King County, Washington, 2004. Infection Control and Hospital Epidemiology, 28, 537–543.
3.
BridgesC.ThompsonW.MeltzerM.ReeveG.TalamontiW.CoxN.FukudaK. (2000). Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. Journal of the American Medical Association, 284, 1655–63.
Centers for Disease Control and Prevention. (2012b). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR, 61, 816–819. Retrieved from http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6140a4.htm
FileT. M.Jr.MarrieT. J. (2010). Burden of community-acquired pneumonia in North American adults. Post Graduate Medicine, 122, 130–141.
12.
FishbeinD.FontanesiJ.KopaldD.StevensonJ.BennettN.StrykerD.SheferA. (2005). Why do not patients receive influenza vaccine in December and January?Vaccine, 24, 798–802.
GilchristS.NanniA.LevineO. (2012). Benefits and effectiveness of administering pneumococcal polysaccharide vaccine with seasonal influenza vaccine: An approach for policymakers. American Journal of Public Health, 102, 596–605.
15.
HighK. (2007). Immunization in older adults. Clinics in Geriatric Medicine, 23, 669–685.
16.
HighK. (2009). Overcoming barriers to adult immunization. The Journal of the American Osteopathic Association, 109, S25–S28.
17.
HuangS.JohnsonK.RayG.WroeP.LieuT.MooreM.FinkelsteinJ. (2011). Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine, 29, 3398–3412. doi:10.1016/j.vaccine.2011.02.088
18.
JohnsonD.NicholK.LipczynskiK. (2008). Barriers to adult immunization. The American Journal of Medicine, 121, S28–S35.
19.
LeeG.MurphyT.LettS.CorteseM.KretsingerK.SchauerS.LieuT. (2007). Cost effectiveness of pertussis vaccination in adults. American Journal of Preventive Medicine, 32, 186–193.
20.
NewallA.KellyH.HarsleyS.ScuffhamP. (2009). Cost effectiveness of influenza vaccination in older adults: A critical review of economic evaluations for the 50–64 year age group. Pharmacoeconomics, 27, 439–450.
21.
NicholK.D'HeillyS.GreenbergM.EhlingerE. (2009). Burden of influenza-like illness and effectiveness of influenza vaccination among working adults aged 50–64 years. Clinical Infectious Diseases, 48, 292–298.
22.
NowalkM.ZimmermanR.FeghaliJ. (2004). Missed opportunities for adult immunization in diverse primary office settings. Vaccine, 22, 3457–3463.
23.
OsterholmT.KelleyN.SommerA.BelongiaE. (2012). Efficacy and effectiveness of influenza vaccines: A systematic review and meta-analysis. Lancet Infectious Diseases, 12, 36–44.
24.
ProsserL.LavelleT.FioreA.BridgesC.ReedC.JainS.MeltzerM. (2011). Cost-effectiveness of 2009 Pandemic Influenza A (H1N1) vaccination in the United States. PLoS ONE, 6, e22308.
25.
RehmS.FarleyM.FileT.HallW.HopkinsR.LevineO.SchaffnerW. (2009). Higher pneumococcal disease vaccination rates needed to protect more at-risk U.S. adults. Postgraduate Medicine, 121, 101–105.
26.
RittleC. (2010). Pertussis: The case for universal vaccination. Journal for Specialists in Pediatric Nursing, 15, 282–291.
27.
SmithK.WateskaA.NowalkM.RaymundM.NourtiJ.ZimmermanR. (2012). Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. Journal of the American Medical Association, 307, 804–812.
28.
TartofS.LewisM.KenyonC.WhiteK.OsbornA.LikoJ.SkoffT. (2013). Waning immunity to pertussis following 5 doses of DTaP. Pediatrics, 131, e1047–e1052. doi: 10.1542/peds.2012-1928
29.
Tora-RocamoraI.DelclosG.MartinezJ.JardiJ.AlbertiC.Man-ZaneraR.BenavidesF. (2012). Occupational health impact of the 2009 H1N1 flu pandemic: Surveillance of sickness absence. Occupational & Environmental Medicine, 69, 205–210.
30.
Vila-CorcolesA. (2007). Advances in pneumococcal vaccines: “What are the advantages for the elderly?Drugs Aging, 24, 791–800.
WeyckerD.StruttonD.EdelsbergJ.SatoR.JacksonL. (2010). Clinical and economic burden of pneumococcal disease in older US adults. Vaccine, 28, 4955–4960.
33.
WolickiJ. (2013, October). Proceedings from the Allegheny County Immunization Coalition (ACIC) annual conference '13: Immunization update, Pittsburgh, PA.
34.
WroeP.FinkelsteinJ.RayT.LinderJ.JohnsonK.Rifas-ShimanS.HuangS. (2012). Aging population and future burden of pneumococcal pneumonia in the United States. The Journal of Infectious Diseases. 205, 1589–1592.
35.
ZimmermanR.WiringaA.NowalkM.LinC.RousculpM.MitgangE.LeeB. (2012). The comparative value of various employer-sponsored influenza vaccination clinics. Journal of Environmental and Occupational Medicine, 54, 1107–1117.
36.
ZivnaI.BerginD.CasavantJ.FontecchioS.NelsonS.KelleyA.EllisonR. (2007). Impact of Bordetella pertussis exposures on a Massachusetts tertiary care medical system. Infection Control and Hospital Epidemiology, 28, 708–712.
